Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
| ▸ | LOX | P28300 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8404700 | 0.85 | SMN1; SMN2 (0.58) | SMN1; SMN2CA2HPGDKMT2AMCHR1 | |
| SCHEMBL8404703 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2CA2NPC1HPGDRAB9A | |
| SCHEMBL6674215 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2CA2KMT2AMCHR1LOXL2 | |
| SCHEMBL24808224 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2CA2NPC1HPGDKMT2A | |
| SCHEMBL23568255 | 0.82 | SMN1; SMN2 (0.57) | SMN1; SMN2CA2NPC1HPGDKMT2A | |
| SCHEMBL8404711 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2CA2NPC1HPGDKMT2A | |
| SCHEMBL19634404 | 0.79 | LOXL2 (0.64) | NPC1HPGDKMT2AMCHR1LOXL2 | |
| SCHEMBL13360594 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2CA2NPC1HPGDRAB9A | |
| SCHEMBL2650933 | 0.79 | MAPT (0.53) | SMN1; SMN2NPC1HPGDRAB9AKMT2A | |
| SCHEMBL19634682 | 0.78 | KMT2A (0.55) | SMN1; SMN2NPC1HPGDRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160297768-A1 | NOVEL IMIDAZOLE DERIVATIVES AND THERAPEUTIC USE THEREOF | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297768-A1 | NOVEL IMIDAZOLE DERIVATIVES AND THERAPEUTIC USE THEREOF | TP53, BAD, API5 | SMN1; SMN2 3608/4885CA2 2085/4885NPC1 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.